Nordea Investment Management AB Increases Stock Holdings in Cencora, Inc. $COR

Nordea Investment Management AB grew its holdings in Cencora, Inc. (NYSE:COR) by 4.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,210,644 shares of the company’s stock after purchasing an additional 52,693 shares during the quarter. Nordea Investment Management AB’s holdings in Cencora were worth $373,823,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Atlantic Edge Private Wealth Management LLC increased its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC raised its position in shares of Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Caldwell Trust Co acquired a new stake in Cencora during the second quarter worth approximately $46,000. Salomon & Ludwin LLC lifted its position in shares of Cencora by 638.1% during the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock worth $47,000 after buying an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC boosted its holdings in shares of Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after buying an additional 159 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COR. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Wells Fargo & Company boosted their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.50.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total transaction of $1,750,221.20. Following the sale, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. This represents a 6.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 in the last quarter. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $342.11 on Tuesday. Cencora, Inc. has a 52 week low of $233.61 and a 52 week high of $377.54. The company has a 50-day moving average price of $349.92 and a 200 day moving average price of $318.78. The company has a market cap of $66.37 billion, a P/E ratio of 43.03, a PEG ratio of 1.60 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the firm earned $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.